CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00811850
NCT00811850Phase 4Completed
CompareCT.gov

Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

Allergan·interventional·Posted Dec 19, 2008·Updated Apr 24, 2019

In Brief

A Phase 4 clinical trial evaluating fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution and fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution for Glaucoma. Completed, enrolled 15 participants across 1 site.

Detailed Summary

A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 19, 2008
Enrollment StartDec 1, 2008
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.5 years ago

Interventions

fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solutiondrug

1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks

fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solutiondrug

1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks